ATE226643T1 - Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs - Google Patents

Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs

Info

Publication number
ATE226643T1
ATE226643T1 AT95927253T AT95927253T ATE226643T1 AT E226643 T1 ATE226643 T1 AT E226643T1 AT 95927253 T AT95927253 T AT 95927253T AT 95927253 T AT95927253 T AT 95927253T AT E226643 T1 ATE226643 T1 AT E226643T1
Authority
AT
Austria
Prior art keywords
treatment
gstp1
prostate cancer
pharmaceutical products
genetic diagnosis
Prior art date
Application number
AT95927253T
Other languages
English (en)
Inventor
William G Nelson
William B Isaacs
Wen-Hsiang Lee
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE226643T1 publication Critical patent/ATE226643T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95927253T 1994-07-19 1995-07-18 Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs ATE226643T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/277,202 US5552277A (en) 1994-07-19 1994-07-19 Genetic diagnosis of prostate cancer
PCT/US1995/009050 WO1996002674A1 (en) 1994-07-19 1995-07-18 Genetic diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
ATE226643T1 true ATE226643T1 (de) 2002-11-15

Family

ID=23059841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927253T ATE226643T1 (de) 1994-07-19 1995-07-18 Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs

Country Status (11)

Country Link
US (1) US5552277A (de)
EP (1) EP0771362B1 (de)
JP (2) JP3774473B2 (de)
AT (1) ATE226643T1 (de)
AU (1) AU695420B2 (de)
CA (1) CA2195396C (de)
DE (1) DE69528653T2 (de)
DK (1) DK0771362T3 (de)
ES (1) ES2186725T3 (de)
PT (1) PT771362E (de)
WO (1) WO1996002674A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US6617434B1 (en) * 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5817497A (en) 1996-11-26 1998-10-06 Incyte Pharmaceuticals Glutathione s-transferase
AUPP312998A0 (en) * 1998-04-23 1998-05-14 Commonwealth Scientific And Industrial Research Organisation Diagnostic assay
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
EP1100903A1 (de) * 1998-07-24 2001-05-23 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Pb 39, ein dysreguliertes gen in prostatakrebs und deren verwendung
US6994991B1 (en) 1998-11-18 2006-02-07 North Shore - Long Island Jewish Research Institute Identification of differentially methylated multiple drug resistance loci
GB9903841D0 (en) * 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
US6783933B1 (en) * 1999-09-15 2004-08-31 The Johns Hopkins University School Of Medicine CACNA1G polynucleotide, polypeptide and methods of use therefor
US6709818B1 (en) * 1999-10-13 2004-03-23 The Johns Hopkins University School Of Medicine Methods of diagnosing and treating hepatic cell proliferative disorders
US6911306B1 (en) * 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
DE60136277D1 (de) * 2000-07-19 2008-12-04 Takara Bio Inc Verfahren zum nachweis von krebs
WO2002014557A1 (en) 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnosis and treatment of tumor-suppressor associated disorders
US7662549B1 (en) * 2000-10-27 2010-02-16 The University Of Southern California Methylation altered DNA sequences as markers associated with human cancer
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
WO2002068694A1 (en) * 2001-02-23 2002-09-06 The Johns Hopkins University School Of Medicine Differentially methylated sequences in pancreatic cancer
US20030045497A1 (en) * 2001-07-27 2003-03-06 Geneinvent Bbl Ab Methylation resistant vectors
SE0102627L (sv) * 2001-07-27 2002-11-19 Geneinvent Bbl Ab Vektorer motståndskraftiga mot metylering
WO2003048332A2 (en) * 2001-11-30 2003-06-12 The Johns Hopkins University METHODS FOR ANALYZING METHYLATED CpG ISLANDS AND GC RICH REGIONS
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
ES2253461T3 (es) * 2002-03-05 2006-06-01 Epigenomics Ag Procedimiento y dispositivo para la determinacion de la especificidad del tejido y del adn que flota libre en tejidos corporales.
WO2004003003A1 (en) * 2002-06-27 2004-01-08 The Johns Hopkins University School Of Medicine Methods for identifying cancer risk
AU2003256995A1 (en) * 2002-07-26 2004-02-16 The Johns Hopkins University Method for identifying cancer risk
AU2003236461B2 (en) 2002-08-29 2009-05-28 Epigenomics Ag Improved method for bisulfite treatment
ATE373673T1 (de) * 2003-01-29 2007-10-15 Hoffmann La Roche Verbessertes verfahren zur behandlung durch bisulfit
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US20060183128A1 (en) * 2003-08-12 2006-08-17 Epigenomics Ag Methods and compositions for differentiating tissues for cell types using epigenetic markers
ATE553218T1 (de) 2003-10-21 2012-04-15 Orion Genomics Llc Differentielle enzymatische fragmetierung
WO2005054502A1 (en) 2003-12-02 2005-06-16 Roche Diagnostics Gmbh Improved method for bisulfite treatment
WO2005118872A2 (en) * 2004-06-01 2005-12-15 The Regents Of The University Of Michigan Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
US7439024B2 (en) * 2005-06-01 2008-10-21 The United States Of America As Represented By The Department Of Veterans Affairs Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
EP1904649A2 (de) * 2005-07-18 2008-04-02 Epigenomics AG Zusammenstellung und verfahren zur krebsdiagnostik mit hilfe von pan-krebs-marker
US7906288B2 (en) * 2006-01-04 2011-03-15 The Johns Hopkins University Compare-MS: method rapid, sensitive and accurate detection of DNA methylation
WO2008083098A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
WO2011037936A2 (en) * 2009-09-24 2011-03-31 Oregon Health & Science University Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer
PL2493496T3 (pl) 2009-10-30 2017-03-31 Medizinische Universität Wien Zastosowanie GSTP1
GB0922085D0 (en) 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
US20140274757A1 (en) 2013-03-14 2014-09-18 Marie K. Kirby Differential Methylation Level of CpG Loci That Are Determinative of a Biochemical Reoccurrence of Prostate Cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686766T2 (de) * 1985-11-21 1993-04-22 Teijin Ltd Monoklonaler antikoerper gegen glutathion s-transferase und dessen verwendung zur diagnose von krebs.
US5073677A (en) * 1986-09-26 1991-12-17 Ciba-Geigy Corporation Herbicidal tolerant plants containing rat glutathione S-transferase gene
WO1990012088A1 (en) * 1989-04-13 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce MONOCLONAL ANTIBODIES TO HUMAN GLUTATHIONE S TRANSFERASE Pi
JPH0425763A (ja) * 1990-05-21 1992-01-29 Maruko Seiyaku Kk グルタチオンＳ―トランスフェラーゼπの定量方法および診断のための試薬

Also Published As

Publication number Publication date
AU695420B2 (en) 1998-08-13
DK0771362T3 (da) 2003-02-17
EP0771362B1 (de) 2002-10-23
PT771362E (pt) 2003-03-31
US5552277A (en) 1996-09-03
DE69528653T2 (de) 2003-07-03
AU3134195A (en) 1996-02-16
JP2006089500A (ja) 2006-04-06
WO1996002674A1 (en) 1996-02-01
ES2186725T3 (es) 2003-05-16
CA2195396A1 (en) 1996-02-01
EP0771362A1 (de) 1997-05-07
DE69528653D1 (de) 2002-11-28
JPH10504187A (ja) 1998-04-28
JP3774473B2 (ja) 2006-05-17
CA2195396C (en) 2009-09-15

Similar Documents

Publication Publication Date Title
DE69528653D1 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
DE69635848D1 (de) Verfahren zum Nachweis von Ki-ras Mutationen
PT1259248E (pt) Metodos para tratar, rastrear e detectar cancros que expressam o factor de crescimento vascular endotelial d
GB9411671D0 (en) Tumor diagnosis and prognosis
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
DE69604509D1 (de) Vorrichtung zur verabreichung von medikamenten und genen durch elektroporation
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
ATE307536T1 (de) Vorrichtung zur erfassung des katheter- gewebekontaktes sowie von wechselwirkungen mit dem gewebe bei der katheterablation
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
TR199902828T2 (xx) Lizofosfolipidlerin de�i�mi� konsantrasyonlar� ile birle�tirilmi� kanser belirleme y�ntemi.
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
EP0567230A3 (de) Verfahren und Vorrichtung zum Nachweis von Mikroorganismen in Kulturfläschchen.
ATE321886T1 (de) Oligonukleotide und diese enthaltende komplexe zur detektion der anwesenheit oder abwesenheit einer zielnukleinsäure in einer probe
DE69228824D1 (de) NACHWEISMETHODEN FÜR C-Raf-1-GENES.5
DE69329062D1 (de) Verwendung von inhibitoren der 3-hydroxy-3-methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie
ATE283478T1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
DE69822149D1 (de) Erkennung von tmorspezifische genprodukte
AU2934299A (en) Detection of apoptotic products
ATE454467T1 (de) Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen
WO2002044419A3 (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
ATE92770T1 (de) Mittel zum nachweis einer fibrinolytischen wirkung.
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23
IL135705A0 (en) Using polyamide nuceic acid oligomers to engender a biological response
DE59712247D1 (de) Mammakarzinom-assoziiertes gen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0771362

Country of ref document: EP